[ad_1] For the first time ever, India’s largest drug maker, Sun Pharmaceutical, saw its US sales of innovative medicines overtake its generics sales in the second quarter of the financial year. The growth was primarily led by the sale of Ilumya, used for the treatment of psoriasis; the ophthalmic product Cequa; and the skin cancer…
[ad_1] For the first time ever, India’s largest drug maker Sun Pharmaceutical saw its US sales of innovative medicines overtaking generics sales in the second quarter of the financial year. The growth was primarily led by the sale of Ilumya, used for treatment of psoriasis; ophthalmic product Cequa and skin cancer drug Odomzo, a top…
[ad_1] Tildrakizumab Shows Significant Efficacy in Psoriatic Arthritis Phase 3 Trials We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] India’s largest drug maker Sun Pharmaceutical has no plans to further expand its manufacturing base in the US even as potential reciprocal tariff remains a significant unknown that could disrupt the sector that operates on thin margins. “We have a significant footprint in the United States and at this time we have no plans…